AlphaMadera's AlphaVal page computes Indivior Pharmaceuticals Inc's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag INDV as undervalued, fairly valued, or overvalued.

What is Indivior Pharmaceuticals Inc's fair value?

Fair value for INDV is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value INDV?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from INDV's most recent reported fundamentals.

INDV - Indivior Pharmaceuticals Inc

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $44.67 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 26.2% above fair value

Current Price $37.53

Bear Case $25.48 32.1% downside ($25.48 - $37.53) / $37.53 = -32.1% $1.64 × 16x P/E

Fair Value $29.73 20.8% downside ($29.73 - $37.53) / $37.53 = -20.8% $1.64 × 18x P/E

Bull Case $33.98 9.5% downside ($33.98 - $37.53) / $37.53 = -9.5% $1.64 × 21x P/E

Adjust Assumptions

P/E Multiple

18.1x

Adjusted EPS

1.64$

Key Value Driver

Normalized P/E multiple (18x base case)

Implied Market Multiple 22.9x

Plain-Language Summary

Applying a 18x P/E to adjusted EPS of $1.64, the base-case value is $29.73 per share.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples